CorMedix Inc. (CRMD) AI Stock Analysis

CorMedix Inc. is a biopharmaceutical company dedicated to advancing therapeutic products aimed at preventing and treating infectious and inflammatory diseases globally. Central to its portfolio is DefenCath/Neutrolin, an anti-infective solution specifically designed to reduce and prevent catheter-related infections and thrombosis in patients requiring central venous catheters across clinical settings such as hemodialysis, total parenteral nutrition, and oncology. Headquartered in Berkeley Heights, New Jersey, the company was formerly known as Picton Holding Company, Inc. before changing its name in January 2007. CorMedix employed 191 people as of October 2026.

CorMedix expanded rapidly following commercialization, generating $311.7M in revenue in FY2025 compared to $43.5M in FY2024 and just $65,408 in FY2022. FY2025 gross margin stood at 88.5%, with an operating margin of 48.2% and net income of $163.1M, translating to EPS of $2.15. This marked a sharp turnaround from FY2024 net income of -$17.9M. Over the trailing twelve months ending June 30, 2026, revenue totaled $462.2M with a profit margin of 40.5%. In the latest quarter ended June 30, 2026, quarterly revenue grew 156.5% year-over-year, while quarterly earnings increased 6.7%.

As of June 30, 2026, CorMedix held $256.7M in cash and short-term investments alongside total debt of $145.2M, resulting in net cash of $111.5M. Total assets were $904.1M against shareholders' equity of $460.8M, supporting a current ratio of 2.56 and a debt-to-equity ratio of 0.31. Operating cash flow reached $175.0M in FY2025, yielding free cash flow of $172.8M after capital expenditures of $2.3M. Over the trailing five years, the company's share count increased 142.6%.

At $7.26 per share, CorMedix carries a market capitalization of $565.9M and an enterprise value of $487.1M. The stock trades at a trailing price-to-earnings multiple of 3.5x, well below the 24.6x median of its US-listed Healthcare peers. Its enterprise value-to-EBITDA ratio of 1.9x is also lower than the peer median of 12.0x, while its price-to-sales multiple is 1.2x versus 4.1x for peers. Over the past year, CRMD shares declined 28.0%, lagging the S&P 500 return of 16.8%. Over five years, the stock gained 46.7% compared to 83.0% for the index.

Wall Street coverage includes 3 Strong Buy and 3 Buy ratings, with zero Hold, Sell, or Strong Sell recommendations. The mean price target is $15.33, representing 111.2% upside above the last close of $7.26. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $337.1M and EPS of $0.49. For the next fiscal year, 6 analysts forecast revenue to fall 14.2% to $289.3M, with EPS declining 88.5% to $0.06. CorMedix beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of CorMedix Inc. (CRMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CRMD income statement, CRMD balance sheet, CRMD key metrics, CRMD analyst forecast, CRMD chart. See the CRMD stock overview for the latest quote and news.